CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, RBC Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP) stock from $42 to $50. The firm kept the Sector Perform rating on the shares. RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform The analysts noted that CASGEVY, CRISPR’s leading product, missed its sales expectations in Q3 2025 – revenue from the product was $17 million, comp ...

Core Insights - Cathie Wood's investment strategy focuses on disruptive innovation, with significant gains in the ARK Innovation ETF (ARKK) up 58% year to date, outperforming broader benchmarks [2] - The current portfolio adjustments emphasize biotech stocks and AI-adjacent platforms, indicating a strategic shift towards sectors with potential catalysts [3][5] Investment Strategy - Wood is methodically reweighting her portfolio to align with anticipated trends in the second half of the year, particularly in biotech and AI [4] - Recent portfolio changes include trimming positions in overvalued stocks while increasing stakes in companies with promising scientific advancements [5] Major Investments - A notable investment includes acquiring 750,000 shares of Intellia Therapeutics (NTLA) valued at $19.2 million, focusing on transformative CRISPR therapies for rare diseases [6] - ARK Invest also made a significant $30.7 million investment in Block, acquiring 385,585 shares, reflecting confidence in fintech infrastructure and the convergence of AI and payments [9][10] Additional Holdings - Smaller strategic additions include 268,833 shares of DraftKings worth $8.9 million, 17,579 shares of Amazon valued at $3.9 million, and 14,881 shares of Alibaba worth $2.6 million [11] - The genomic sector saw growth with the addition of 562,505 shares of Pacific Biosciences and 274,939 shares of 10x Genomics [11]

Group 1: Company Overview - CRISPR Therapeutics AG (NASDAQ:CRSP) is recognized as a leading biotech stock, particularly noted for its gene-editing technology and proprietary gene sequencing platform aimed at developing precise treatments for diseases requiring DNA modification [3]. Group 2: Recent Developments - The company has entered into a collaboration with Sirius on FXI siRNA SRSD107, leading to the initiation of a Phase II trial focused on the prevention of venous thromboembolism (VTE), which does not involve gene editing [1]. - BMO Capital has reaffirmed an Outperform rating and a price target of $75 for CRISPR Therapeutics AG following this collaboration [1]. Group 3: Market Potential - Clinical studies indicate that FXI is a promising target that could disrupt the $15 billion thromboembolism market, which is currently dominated by Factor X-targeting medications [2]. - Approximately 40% of individuals with atrial fibrillation are either untreated or only partially treated, highlighting a significant demand for innovative treatments in this sector [2].